Carrie Anderson - Integra LifeSciences President
| IART Stock | USD 22.49 0.22 0.97% |
President
Ms. Carrie L. Anderson is Chief Financial Officer and Principal Financial Officer, Corporationrationrate Vice President of the Company. Ms. Anderson most recently served as chief accounting officer and corporate controller at Dover Corporationrationration, a global industrial manufacturer with 20 operating companies, where she was responsible for corporate accounting and FPA across Europe, India and China. In addition, Ms. Anderson served as chief financial officer for two of Dovers operating segments. Prior to Dover Corporationrationration, Ms. Anderson spent over a decade at Aptiv PLC, serving in various finance functions, including capital planning and investor relations, and ultimately, global segment chief financial officer. She began her career with General Motors in 1991 since 2019.
| Age | 55 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Phone | 609 275 0500 |
| Web | https://www.integralife.com |
Carrie Anderson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Carrie Anderson against Integra LifeSciences stock is an integral part of due diligence when investing in Integra LifeSciences. Carrie Anderson insider activity provides valuable insight into whether Integra LifeSciences is net buyers or sellers over its current business cycle. Note, Integra LifeSciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Integra LifeSciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Carrie Anderson over a year ago Disposition of tradable shares by Carrie Anderson of Campbell Soup at 41.26 subject to Rule 16b-3 |
Integra LifeSciences Management Efficiency
The company has return on total asset (ROA) of 0.0291 % which means that it generated a profit of $0.0291 on every $100 spent on assets. This is way below average. Integra LifeSciences' management efficiency ratios could be used to measure how well Integra LifeSciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Stanley Peters | CONMED | 45 | |
| Roy Galvin | Haemonetics | 54 | |
| Anila Lingamneni | Haemonetics | 57 | |
| James Darecca | Haemonetics | 50 | |
| Joseph Wright | Merit Medical Systems | 55 | |
| Johonna Pelletier | CONMED | 51 | |
| Daniel Woolson | ICU Medical | 47 | |
| Daniel Jonas | CONMED | 56 | |
| Michelle Basil | Haemonetics | 52 | |
| Terence Berge | CONMED | 54 | |
| Stanley III | CONMED | 49 | |
| Virginia Sanzone | ICU Medical | 50 | |
| Stewart Strong | Haemonetics | 58 | |
| Heather Cohen | CONMED | 51 | |
| David Murray | CONMED | 77 | |
| John Kennedy | CONMED | 66 | |
| Patrick Beyer | CONMED | 59 | |
| Todd Garner | CONMED | 55 | |
| William Burke | Haemonetics | 52 | |
| Jacqueline Scanlan | Haemonetics | 46 | |
| Peter Shagory | CONMED | 56 | |
Management Performance
| Return On Equity | -0.0044 | ||||
| Return On Asset | 0.0291 |
Integra LifeSciences Leadership Team
Elected by the shareholders, the Integra LifeSciences' board of directors comprises two types of representatives: Integra LifeSciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Integra. The board's role is to monitor Integra LifeSciences' management team and ensure that shareholders' interests are well served. Integra LifeSciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Integra LifeSciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth Burhop, Chief Scientific Officer, Corporate Vice President | ||
| Ruth Fleming, Vice Marketing | ||
| Eric Schwartz, Corporate Vice President General Counsel, Secretary | ||
| Lea Knight, Executive CFO | ||
| Mathieu Aussermeier, Investor Finance | ||
| Robert Davis, President of Specialty Surgical Solutions and Corporate VP | ||
| Christopher Ward, Senior Relations | ||
| Maria Platsis, Sr Devel | ||
| William Compton, Chief VP | ||
| Chantal VeillonBerteloot, Executive Officer | ||
| Jeffrey Mosebrook, Principal Accounting Officer, Vice President Corporate Controller | ||
| Susan Krause, Corporate Officer | ||
| Stuart Hart, Corporate Officer | ||
| Mark Jesser, Corporate Officer | ||
| Jan Witte, CEO President | ||
| Mojdeh Poul, CEO President | ||
| Laurene Isip, Vice Relations | ||
| Michael McBreen, Executive Surgical | ||
| Carrie Anderson, CFO and Principal Financial Officer, Corporate Vice President | ||
| Eric JD, Chief VP | ||
| Stuart Essig, Chairman of the Board | ||
| Jessica Smith, Corporate Officer | ||
| Stephen Leonard, Corporate Chain |
Integra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Integra LifeSciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0044 | ||||
| Return On Asset | 0.0291 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 3.45 B | ||||
| Shares Outstanding | 77.22 M | ||||
| Shares Owned By Insiders | 14.24 % | ||||
| Shares Owned By Institutions | 91.50 % | ||||
| Number Of Shares Shorted | 3.5 M | ||||
| Price To Earning | 26.94 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.